These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 26558612

  • 1. Novel Activities of Select NSAID R-Enantiomers against Rac1 and Cdc42 GTPases.
    Oprea TI, Sklar LA, Agola JO, Guo Y, Silberberg M, Roxby J, Vestling A, Romero E, Surviladze Z, Murray-Krezan C, Waller A, Ursu O, Hudson LG, Wandinger-Ness A.
    PLoS One; 2015; 10(11):e0142182. PubMed ID: 26558612
    [Abstract] [Full Text] [Related]

  • 2. R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis.
    Guo Y, Kenney SR, Muller CY, Adams S, Rutledge T, Romero E, Murray-Krezan C, Prekeris R, Sklar LA, Hudson LG, Wandinger-Ness A.
    Mol Cancer Ther; 2015 Oct; 14(10):2215-27. PubMed ID: 26206334
    [Abstract] [Full Text] [Related]

  • 3. The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo.
    Grimes MM, Kenney SR, Dominguez DR, Brayer KJ, Guo Y, Wandinger-Ness A, Hudson LG.
    BMC Cancer; 2021 Jan 07; 21(1):40. PubMed ID: 33413202
    [Abstract] [Full Text] [Related]

  • 4. A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer Patients.
    Guo Y, Kenney SR, Cook L, Adams SF, Rutledge T, Romero E, Oprea TI, Sklar LA, Bedrick E, Wiggins CL, Kang H, Lomo L, Muller CY, Wandinger-Ness A, Hudson LG.
    Clin Cancer Res; 2015 Nov 15; 21(22):5064-72. PubMed ID: 26071482
    [Abstract] [Full Text] [Related]

  • 5. Characterization of a Cdc42 protein inhibitor and its use as a molecular probe.
    Hong L, Kenney SR, Phillips GK, Simpson D, Schroeder CE, Nöth J, Romero E, Swanson S, Waller A, Strouse JJ, Carter M, Chigaev A, Ursu O, Oprea T, Hjelle B, Golden JE, Aubé J, Hudson LG, Buranda T, Sklar LA, Wandinger-Ness A.
    J Biol Chem; 2013 Mar 22; 288(12):8531-8543. PubMed ID: 23382385
    [Abstract] [Full Text] [Related]

  • 6. Maspin controls mammary tumor cell migration through inhibiting Rac1 and Cdc42, but not the RhoA GTPase.
    Shi HY, Stafford LJ, Liu Z, Liu M, Zhang M.
    Cell Motil Cytoskeleton; 2007 May 22; 64(5):338-46. PubMed ID: 17301947
    [Abstract] [Full Text] [Related]

  • 7. Non-steroidal Anti-inflammatory Drugs Are Caspase Inhibitors.
    Smith CE, Soti S, Jones TA, Nakagawa A, Xue D, Yin H.
    Cell Chem Biol; 2017 Mar 16; 24(3):281-292. PubMed ID: 28238723
    [Abstract] [Full Text] [Related]

  • 8. The role of Rho GTPases' substrates Rac and Cdc42 in osteoclastogenesis and relevant natural medicinal products study.
    Liu Y, Dou Y, Yan L, Yang X, He B, Kong L, Smith W.
    Biosci Rep; 2020 Jul 31; 40(7):. PubMed ID: 32578854
    [Abstract] [Full Text] [Related]

  • 9. Dual Actions of Ketorolac in Metastatic Ovarian Cancer.
    Hudson LG, Cook LS, Grimes MM, Muller CY, Adams SF, Wandinger-Ness A.
    Cancers (Basel); 2019 Jul 24; 11(8):. PubMed ID: 31344967
    [Abstract] [Full Text] [Related]

  • 10. DEF6, a novel PH-DH-like domain protein, is an upstream activator of the Rho GTPases Rac1, Cdc42, and RhoA.
    Mavrakis KJ, McKinlay KJ, Jones P, Sablitzky F.
    Exp Cell Res; 2004 Apr 01; 294(2):335-44. PubMed ID: 15023524
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of Cdc42 and Rac1 activities in pheochromocytoma, the adrenal medulla tumor.
    Croisé P, Brunaud L, Tóth P, Gasman S, Ory S.
    Small GTPases; 2017 Apr 03; 8(2):122-127. PubMed ID: 27355516
    [Abstract] [Full Text] [Related]

  • 12. MeHg affects the activation of FAK, Src, Rac1 and Cdc42, critical proteins for cell movement in PDGF-stimulated SH-SY5Y neuroblastoma cells.
    Hernández AJA, Reyes VL, Albores-García D, Gómez R, Calderón-Aranda ES.
    Toxicology; 2018 Feb 01; 394():35-44. PubMed ID: 29197552
    [Abstract] [Full Text] [Related]

  • 13. Discovery and characterization of small molecule Rac1 inhibitors.
    Arnst JL, Hein AL, Taylor MA, Palermo NY, Contreras JI, Sonawane YA, Wahl AO, Ouellette MM, Natarajan A, Yan Y.
    Oncotarget; 2017 May 23; 8(21):34586-34600. PubMed ID: 28410221
    [Abstract] [Full Text] [Related]

  • 14. Unraveling the molecular mechanism of interactions of the Rho GTPases Cdc42 and Rac1 with the scaffolding protein IQGAP2.
    Ozdemir ES, Jang H, Gursoy A, Keskin O, Li Z, Sacks DB, Nussinov R.
    J Biol Chem; 2018 Mar 09; 293(10):3685-3699. PubMed ID: 29358323
    [Abstract] [Full Text] [Related]

  • 15. Metformin impairs Rho GTPase signaling to induce apoptosis in neuroblastoma cells and inhibits growth of tumors in the xenograft mouse model of neuroblastoma.
    Kumar A, Al-Sammarraie N, DiPette DJ, Singh US.
    Oncotarget; 2014 Nov 30; 5(22):11709-22. PubMed ID: 25365944
    [Abstract] [Full Text] [Related]

  • 16. Multiple factors confer specific Cdc42 and Rac protein activation by dedicator of cytokinesis (DOCK) nucleotide exchange factors.
    Kulkarni K, Yang J, Zhang Z, Barford D.
    J Biol Chem; 2011 Jul 15; 286(28):25341-51. PubMed ID: 21613211
    [Abstract] [Full Text] [Related]

  • 17. Stereoselective inhibitory effect of flurbiprofen, ibuprofen and naproxen on human organic anion transporters hOAT1 and hOAT3.
    Honjo H, Uwai Y, Aoki Y, Iwamoto K.
    Biopharm Drug Dispos; 2011 Dec 15; 32(9):518-24. PubMed ID: 22072415
    [Abstract] [Full Text] [Related]

  • 18. The Intrinsic GDP/GTP Exchange Activities of Cdc42 and Rac1 Are Critical Determinants for Their Specific Effects on Mobilization of the Actin Filament System.
    Aspenström P.
    Cells; 2019 Jul 21; 8(7):. PubMed ID: 31330900
    [Abstract] [Full Text] [Related]

  • 19. Different roles of the small GTPases Rac1, Cdc42, and RhoG in CALEB/NGC-induced dendritic tree complexity.
    Schulz J, Franke K, Frick M, Schumacher S.
    J Neurochem; 2016 Oct 21; 139(1):26-39. PubMed ID: 27412363
    [Abstract] [Full Text] [Related]

  • 20. RAC1 GTP-ase signals Wnt-beta-catenin pathway mediated integrin-directed metastasis-associated tumor cell phenotypes in triple negative breast cancers.
    De P, Carlson JH, Jepperson T, Willis S, Leyland-Jones B, Dey N.
    Oncotarget; 2017 Jan 10; 8(2):3072-3103. PubMed ID: 27902969
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.